Wyllie Cornwell - Pfizer Independent Director

<div class='circular--portrait' style='background:#FF0F00;color: #FFFFF0;font-size:3em;padding-top: 38px;;'>PFE</div>
PFE -- USA Stock  

Trending

  Director
Mr. Wyllie Don Cornwell is an Independent Director of Pfizer Inc. He was Chairman of the Board and Chief Executive Officer of Granite Broadcasting Corporationrationration from 1988 until his retirement in August 2009, and served as Vice Chairman of the Board until December 2009. Director of American International Group, Inc. and Avon Products, Inc. Director of the Edna McConnell Clark Foundation. Director of the Wallace Foundation from 2002 until 2012 and previously served as a Director of CVS Caremark for over 10 years. Trustee of Big Brothers Big Sisters of New York City. Through Mr. Cornwells 38year career as an entrepreneur driving the growth of a consumerfocused media company, an executive in the investment banking industry and a director of several significant consumer product and healthcare companies, he has valuable business, leadership and management experience and brings important perspectives on the issues facing Pfizer. Mr. Cornwell founded and built Granite, a consumerfocused media company, through acquisitions and operating growth, enabling him to provide insight and guidance on strategic direction and growth
Age: 71  Director Since 1997      
212 733-2323  www.pfizer.com
Cornwell?s strong financial background, including his work at Goldman Sachs prior to cofounding Granite and his service and leadership on the audit, finance and investment committees of other companies, also provides financial expertise to the Board, including an understanding of financial statements, corporate finance, accounting and capital markets.

Pfizer Management Efficiency

Pfizer Inc has Return on Asset of 8.28 % which means that on every $100 spent on asset it made $8.28 of profit. This is considered to be average in the sector. In the same way, it shows return on shareholders equity (ROE) of 0.0021 % implying that it generated $0.0021 on every 100 dollars invested. Pfizer management efficiency ratios could be used to measure of how well the company is managing its routine affairs as well as how well it utilizes its assets and manages liabilities. The current year Return on Investment is expected to grow to 11.02, whereas Return on Average Assets are expected to decline to 0.08. Pfizer Tax Assets are expected to significantly decrease based on the last few years of reporting. The last year's Tax Assets were at 5.44 Billion. The current year Revenue to Assets is expected to grow to 0.35, whereas Assets Non Current are expected to decline to about 124.2 B. Pfizer Tax Liabilities is expected to significantly decrease based on the last few years of reporting. The last year's Tax Liabilities was at 18.68 Billion
The company has 47.96 B in debt with debt to equity (D/E) ratio of 80.0 . This implies that the company may be unable to create cash to meet all of its financial commitments. Pfizer Inc has Current Ratio of 1.44 which is typical for the industry and considered as normal.

Similar Executives

Showing few of many executives

DIRECTOR Since

Shikha SharmaDr Reddys Laboratories
2019
Bonnie BasslerRegeneron Pharmaceuticals
2016
William DoyleZoetis Inc
2015
Arthur RyanRegeneron Pharmaceuticals
2003
Robert ScullyZoetis Inc
2013
Sanjay KhoslaZoetis Inc
2013
Jeffrey SmithPerrigo Company Plc
2017
Sridar IyengarDr Reddys Laboratories
2011
Theodore SamuelstoPerrigo Company Plc
2017
Lloyd CarneyVertex Pharmaceuticals Incorpor
2019
Michael JandernoaPerrigo Company Plc
2007
Gary CohenPerrigo Company Plc
2009
Ravi BhoothalingamDr Reddys Laboratories
2000
Marc TessierLavigneRegeneron Pharmaceuticals
2011
Rolf ClassonPerrigo Company Plc
2017
Michael BrownRegeneron Pharmaceuticals
1991
Theodore SamuelsPerrigo Company Plc
2017
Leo PuriDr Reddys Laboratories
2018
Gary KunklePerrigo Company Plc
2009
Christine PoonRegeneron Pharmaceuticals
2010
Adriana KaraboutisPerrigo Company Plc
2017

Company Summary

Pfizer Inc. develops, manufactures, and sells healthcare products worldwide. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York. Pfizer operates under Drug ManufacturersGeneral classification in USA and is traded on BATS Exchange. It employs 88300 people.Pfizer Inc (PFE) is traded on BATS Exchange in USA and employs 88,300 people.

Pfizer Inc Leadership Team

John Young, Group President - Pfizer Innovative Health and Angela Hwang
Jennifer Damico, Senior Vice President Principal Accounting Officer, Controller
Frank DAmelio, Chief Financial Officer, Executive Vice President - Business Operations and Global Supply
Douglas Lankler, Executive Vice President General Counsel
Dawn Rogers, Chief Human Resource Officer, Executive Vice President
Helen Hobbs, Independent Director
Shantanu Narayen, Lead Independent Director
James Smith, Independent Director
Dennis Ausiello, Independent Director
Mikael Dolsten, Chief Scientific Officer, President - Worldwide Research, Development and Medical
Susan DesmondHellmann, Director
Frances Fergusson, Independent Director
Stephen Sanger, Independent Director
Lidia Fonseca, Executive Vice President, Chief Technology Officer and Digital Officer
Gordon Loh, Senior Vice President Corporate Audit
Wyllie Cornwell, Independent Director
Suzanne Johnson, Independent Director
Alexander Mackenzie, Executive Vice President Chief Development Officer
Geno Germano, Group President of Global Innovative Pharma Bus.
Laurie Olson, Executive Vice President - Strategy, Portfolio and Commercial Operations
Sally Susman, Chief Corporate Affairs Officer, Executive Vice President
Anthony Maddaluna, Executive Vice President and Presidentident - Pfizer Global Supply
Susan Hockfield, Independent Director
Freda LewisHall, Executive Vice President Chief Medical Officer
Rady Johnson, Chief Compliance, Quality and Risk Officer, Executive Vice President
Dan Littman, Independent Director
Ian Read, Chairman, CEO and Chairman of Executive Committee
James Kilts, Independent Director
Don Cornwell, Independent Director
James Quincey, Independent Director
Charles Hill, Executive Vice President - Worldwide Human Resources
Joseph Echevarria, Independent Director
Albert Bourla, Group President - Vaccines, Oncology and Consumer Healthcare Business
Kirsten LundJurgensen, Executive Vice President and Presidentident - Pfizer Global Supply
Angela Hwang, Group President, Pfizer Biopharmaceuticals Group
Scott Gottlieb, Independent Director
Ronald Blaylock, Independent Director
Kathrin Jansen, Senior Vice President - Vaccine Research & Development
Michael Goettler, Group President - Pfizer Upjohn

Stock Performance Indicators

Did you try this?

Run Portfolio Rebalancing Now

   

Portfolio Rebalancing

Analyze risk-adjusted returns against different time horizons to find asset-allocation targets
All  Next Launch Module

Currently Active Assets on Macroaxis

CRM   
Purchased few shares of
few hours ago
Traded for 174.99
CRM   
Purchased few shares of
few hours ago
Traded for 174.99
RYDAF   
Purchased over 100 shares of
few hours ago
Traded for 17.63
FB   
Purchased few shares of
few hours ago
Traded for 230.16
VMW   
Purchased a lot of shares of
few hours ago
Traded for 149.39
Please check Your Equity Center. Please also try Watchlist Optimization module to optimize watchlists to build efficient portfolio or rebalance existing positions based on mean-variance optimization algorithm.
Macroaxis is not a registered investment advisor or broker/dealer. All investments, including stocks, funds, ETFs, or cryptocurrencies, are speculative and involve substantial risk of loss. We encourage our investors to invest carefully. Much of our information is derived directly from data published by companies or submitted to governmental agencies which we believe are reliable, but are without our independent verification. Therefore, we cannot assure you that the information is accurate or complete. We do not in any way warrant or guarantee the success of any action you take in reliance on our statements or recommendations. Also, note that past performance is not necessarily indicative of future results. All investments carry risk, and all investment decisions of an individual remain the responsibility of that individual. There is no guarantee that systems, indicators, or signals will result in profits or that they will not result in losses. All investors are advised to fully understand all risks associated with any investing they choose to do. Hypothetical or simulated performance is not indicative of future results. We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown because hypothetical or simulated performance is not necessarily indicative of future results. For more information please visit our terms and condition page